Strainprint Joins Global Cannabis Partnership – Expansion Announced With Seven New Members
New members will adhere to the Responsible Cannabis Framework, a world first.
How is Cannabis Quality Tested? Discovering Canada’s 2018 Consumer Protections
The 2018 guidelines for 3rd party testing can be broken down into two main categories: cultivation and production. Here’s a look at some key criteria for these new consumer protections. To find out more, visit the Strainprint Community…
Strainprint Featured in The Growth Op – Strainprint announces research partnership to identify how cannabis can be used to treat endometriosis
Strainprint announces research partnership to identify how cannabis can be used to treat endometriosis
Strainprint™ Technologies, Lumir Lab and Gynica Announce Clinical Trial Partnership Establishing World’s First and Largest Database of Medical Cannabis Effects on Women
International Study Monitoring Real-time Cannabis Treatment for the Symptoms of Endometriosis Will Leverage Strainprint’s Comprehensive Research Platform
Strainprint Featured in the Green Market Report – Cannabis Company President Applies Tech Boom Lessons to Cannabis Industry
Cannabis Company President Applies Tech Boom Lessons to Cannabis Industry
Strainprint Featured in CTV News – Canadian tech companies look to cash in on cannabis with innovations and apps
Strainprint, which has focused on medical marijuana users but works just as well for recreational users, launched the day before legalization to take advantage of the attention pot would garner.
Strainprint Featured in Toronto.com – Canadian Medical Marijuana Analytic App Expands As Pot Becomes Legal
Strainprint Community allows cannabis users to share information
Strainprint™ Technologies Ltd. expands nationwide coverage with the addition of GrowWise Health Education Centres
Enterprise-wide license to Strainprint Analytics, Clinic Edition, will provide unparalleled medical cannabis treatment guidance.
Strainprint Featured in the Regina Leader-Post
For those aged 50 and older, men edged out women with respect to reporting efficacy of top-treated symptoms.